Latest Tokyo Brief coverage on SanBio Company Limited, tracking filings, financial news, and market signals from Japan.
TSE:4592
SanBio's newly launched cell therapy for chronic motor paralysis after traumatic brain injury, priced at ¥72.7mn a treatment, has generated no revenue and no dosed patients four months after its Japanese launch, and the company is now targeting only six cases by the fiscal year-end in January while its cash pile fell ¥2.34bn to ¥12.75bn over the same half-year.
SanBio's cell therapy for chronic traumatic brain injury, known by its development code SB623, cleared its final approval hurdle and reached the market in 2026 with a ¥72mn price tag, yet the company's latest results show no product revenue, a shrinking cash pile, and a 20.29% cut to capital to offset accumulated losses.
The three months to April 30 produced no revenue and an ¥836 million net loss, yet AKUGO was added to Japan's reimbursement list in May at ¥72 million and commercial sales began. SanBio also said it agreed Phase 3 trial design with the FDA for traumatic brain injury, though the company did not disclose early sales volume or hospital uptake.